Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
163.73
-1.54 (-0.93%)
At close: Jan 23, 2026
Jagsonpal Pharmaceuticals Revenue
Jagsonpal Pharmaceuticals had revenue of 729.45M INR in the quarter ending December 31, 2025, a decrease of -1.46%. This brings the company's revenue in the last twelve months to 2.82B, up 11.02% year-over-year. In the fiscal year ending March 31, 2025, Jagsonpal Pharmaceuticals had annual revenue of 2.69B with 28.76% growth.
Revenue (ttm)
2.82B
Revenue Growth
+11.02%
P/S Ratio
3.93
Revenue / Employee
2.01M
Employees
1,399
Market Cap
11.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.69B | 600.14M | 28.76% |
| Mar 31, 2024 | 2.09B | -280.12M | -11.83% |
| Mar 31, 2023 | 2.37B | 191.30M | 8.79% |
| Mar 31, 2022 | 2.18B | 296.38M | 15.77% |
| Mar 31, 2021 | 1.88B | 293.78M | 18.53% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.25B |
| Innova Captab | 13.63B |
| Solara Active Pharma Sciences | 12.06B |
| Windlas Biotech | 8.30B |
| Orchid Pharma | 8.21B |
| RPG Life Sciences | 6.66B |
| Ind-Swift Laboratories | 5.72B |
| Sigachi Industries | 5.09B |
Jagsonpal Pharmaceuticals News
- 2 months ago - Q2 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript - GuruFocus
- 2 months ago - Jagsonpal Pharmaceuticals shares decline nearly 3% today as revenue and EBITDA soften in Q2 - Business Upturn
- 11 months ago - Jagsonpal Pharmaceuticals shares drop 2.6% after USFDA issues warning letter for manufacturing lapses at API plant - Business Upturn
- 1 year ago - Jagsonpal Pharmaceuticals acquires Resilient Cosmeceuticals’ India business for Rs 24 crore - Business Upturn
- 1 year ago - Jagsonpal Pharmaceuticals shares jump nearly 6% on strong Q3 FY25 results - Business Upturn
- 1 year ago - Jagsonpal Pharmaceuticals block trade: 22 lakh shares exchanged in ₹88 crore deal - Business Upturn